Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talnetant in schizophrenia
NCT00300963Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2004
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of talnetant in schizophrenia (3 arms), sponsored by GSK. Primary endpoint: Positive and Negative Syndrome Scale at 6 weeks. Started Dec 2004; status: completed.
02
Drugs
talnetant
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00300963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300963.